glp-1 receptor agonist type 1 diabetes randomized trial agonists and next-generation metabolic hormone therapies in chronic kidney disease Transforming obesity: The advancement of
Description
However patient discontinuation due to adverse effects from treatment was between 18% and 32% for all Efinopegdutide doses, and 17% for Liraglutide [4]
About this article Cite this article Saraiva, J.F.K., Franco, D
Sukumaran and colleagues treated Zucker lean and obese rates with either vehicle or the GLP-1 agonist liraglutide (LIRA) for 8 weeks [66]
Williams recommends a conversation between an eye doctor, primary care doctor, and, if pertinent, a neurologist or other subspecialist, to decide how to proceed with the medication
Of note, in the cost effectiveness study by Lim et al
